Literature DB >> 26494234

Prostate cancer patients' report on communication about endocrine therapy and its association with adherence.

B Jung, C Stoll, G Feick, F J Prott, J Zell, I Rudolph, J Huebner.   

Abstract

BACKGROUND: Endocrine therapy is a mainstay of prostate cancer therapy. Given that few data exist on patient physician communication with regard to this field of therapy and adherence, we conducted a survey of patient members of a German support organization. PATIENTS AND METHODS: We developed a structured questionnaire that was tested in a pilot version and then programmed as an online questionnaire.
RESULTS: The questionnaire was completed by 694 patients. While 58 % of participants rated the information they received as comprehensive, 42 % did not. Fifty-one percentage stated that they were informed of side effects in detail, and 35 % received information on supportive treatments available in the event of side effects. Patients with higher education more often reported receiving information on side effects (p = 0.036) as well as alternatives for treatment (p = 0.001). Only 13 % stated that their questions were answered in detail, with 43 % receiving no answers or only non-detailed answers. Additional information was sought by 82 %, mostly from the Internet (67 %) and patient support groups (66 %). Seventy-six percentage experienced side effects that imposed limitations on their daily activities. Of those patients with side effects, 60 % reported that their physicians did not react to their complaints. There is a significant association between side effects in general and depression in particular and non-adherence (p < 0.01 and p = 0.002, respectively). In contrast, better information on side effects is associated with better adherence (p < 0001).
CONCLUSION: In order to improve adherence, detailed information on side effects and comprehensive supportive care is most important. Physicians should not rely on written information but should rather mainly engage in direct communication.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26494234     DOI: 10.1007/s00432-015-2059-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

1.  Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.

Authors:  Nicolas Mottet; Michel Peneau; Jean-Jacques Mazeron; Vincent Molinie; Pierre Richaud
Journal:  Eur Urol       Date:  2012-04-03       Impact factor: 20.096

Review 2.  Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Authors:  B Nair; T Wilt; R MacDonald; I Rutks
Journal:  Cochrane Database Syst Rev       Date:  2002

3.  Compliance and persistence of endocrine adjuvant breast cancer therapy.

Authors:  Uwe Güth; Mary Elizabeth Myrick; Nerbil Kilic; Serenella Eppenberger-Castori; Seraina Margaretha Schmid
Journal:  Breast Cancer Res Treat       Date:  2012-01       Impact factor: 4.872

4.  Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time.

Authors:  C Cluze; D Rey; L Huiart; M K BenDiane; A D Bouhnik; C Berenger; M P Carrieri; R Giorgi
Journal:  Ann Oncol       Date:  2011-07-25       Impact factor: 32.976

Review 5.  Endocrine complications of androgen-deprivation therapy in men with prostate cancer.

Authors:  Lindsey K Harle; Marcello Maggio; Sadeka Shahani; Milena Braga-Basaria; Shehzad Basaria
Journal:  Clin Adv Hematol Oncol       Date:  2006-09

6.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

7.  Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

Authors:  Yihang Liu; Jennifer L Malin; Allison L Diamant; Amardeep Thind; Rose C Maly
Journal:  Breast Cancer Res Treat       Date:  2012-12-23       Impact factor: 4.872

8.  Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis.

Authors:  Robin J Bell; Pamela Fradkin; Max Schwarz; Susan R Davis
Journal:  Menopause       Date:  2013-01       Impact factor: 2.953

Review 9.  Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Authors:  S Kumar; M Shelley; C Harrison; B Coles; T J Wilt; M D Mason
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 10.  Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.

Authors:  H Payne; M Mason
Journal:  Br J Cancer       Date:  2011-10-18       Impact factor: 7.640

View more
  3 in total

1.  Unmet supportive care needs in Hispanic/Latino cancer survivors: prevalence and associations with patient-provider communication, satisfaction with cancer care, and symptom burden.

Authors:  Patricia I Moreno; Amelie G Ramirez; Sandra L San Miguel-Majors; Leopoldo Castillo; Rina S Fox; Kipling J Gallion; Edgar Munoz; Ryne Estabrook; Arely Perez; Thomas Lad; Courtney Hollowell; Frank J Penedo
Journal:  Support Care Cancer       Date:  2018-08-22       Impact factor: 3.603

2.  The role of the general practitioner in cancer care: a survey of the patients' perspective.

Authors:  V Lang; S Walter; J Fessler; M J Koester; D Ruetters; J Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-10       Impact factor: 4.553

3.  Shared decision making, physicians' explanations, and treatment satisfaction: a cross-sectional survey of prostate cancer patients.

Authors:  Kazuhiro Nakayama; Wakako Osaka; Nobuaki Matsubara; Tsutomu Takeuchi; Mayumi Toyoda; Noriyuki Ohtake; Hiroji Uemura
Journal:  BMC Med Inform Decis Mak       Date:  2020-12-14       Impact factor: 2.796

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.